Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) EBT Margin: 2010-2025

Historic EBT Margin for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -92.91%.

  • Lineage Cell Therapeutics' EBT Margin fell 1350.00% to -92.91% in Q3 2025 from the same period last year, while for Sep 2025 it was -296.07%, marking a year-over-year decrease of 6616.00%. This contributed to the annual value of -195.62% for FY2024, which is 6466.00% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its EBT Margin stood at -92.91% for Q3 2025, which was up 86.71% from -698.95% recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' EBT Margin peaked at -56.02% during Q4 2021, and registered a low of -969.73% during Q2 2021.
  • For the 3-year period, Lineage Cell Therapeutics' EBT Margin averaged around -315.61%, with its median value being -260.14% (2023).
  • Per our database at Business Quant, Lineage Cell Therapeutics' EBT Margin surged by 126,936bps in 2021 and then crashed by 38,852bps in 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' EBT Margin (Quarterly) stood at -56.02% in 2021, then plummeted by 27,620bps to -332.22% in 2022, then spiked by 10,645bps to -225.77% in 2023, then soared by 11,245bps to -113.32% in 2024, then slumped by 1,350bps to -92.91% in 2025.
  • Its last three reported values are -92.91% in Q3 2025, -698.95% for Q2 2025, and -401.26% during Q1 2025.